205 related articles for article (PubMed ID: 34485083)
1. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
Elife; 2023 May; 12():. PubMed ID: 37249220
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Kishnani P; Niederau C; Underhill LH; McClain MR
Am J Hematol; 2020 Sep; 95(9):1038-1046. PubMed ID: 32438452
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy.
Istaiti M; Becker-Cohen M; Dinur T; Revel-Vilk S; Zimran A
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362492
[TBL] [Abstract][Full Text] [Related]
8. A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy.
Komada N; Fujiwara T; Yoshizumi H; Ida H; Shimoda K
Case Rep Gastroenterol; 2021; 15(3):838-845. PubMed ID: 34720832
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1.
Cox TM; Charrow J; Lukina E; Mistry PK; Foster MC; Peterschmitt MJ
Genet Med; 2023 Feb; 25(2):100329. PubMed ID: 36469032
[TBL] [Abstract][Full Text] [Related]
10. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
11. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
[TBL] [Abstract][Full Text] [Related]
12. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
[TBL] [Abstract][Full Text] [Related]
13. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
14. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience.
Duminuco A; Fazio M; Grasso S; Gullo L; Riccobene C; Calafiore V; Markovic U; Di Raimondo F; Giuffrida G
Clin Ther; 2023 Nov; 45(11):1105-1110. PubMed ID: 37722956
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
17. Profile of eliglustat tartrate in the management of Gaucher disease.
Sechi A; Dardis A; Bembi B
Ther Clin Risk Manag; 2016; 12():53-8. PubMed ID: 26811686
[TBL] [Abstract][Full Text] [Related]
18. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.
Tylki-Szymańska A; Szymańska-Rożek P; Hasiński P; Ługowska A
Mol Genet Metab; 2018 Apr; 123(4):495-500. PubMed ID: 29530534
[TBL] [Abstract][Full Text] [Related]
19. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]